Get started
Author

Shuji Arita

Observed names: ARITA, Shuji, S. Arita
Observed institution: Miyazaki Prefectural Hospital
ORCID: 0009-0001-3795-8787
Observed ORCID: 0009-0001-3795-8787
OpenAlex ID: A5055627370
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
2024 · Tomoko Kodama, Takashi Imajima, et al. · Scientific Reports · 14
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
2024 · Taro Shibuki, Taiga Otsuka, et al. · Scientific Reports · 9
PDF
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
2025 · T. Shirakawa, M. Shimokawa, et al. · ESMO Gastrointestinal Oncology · 4
PDF
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer
2025 · Keisuke Miwa, Reina Kawasaki, et al. · Frontiers in Oncology · 2
PDF
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)
2025 · Tomonori Araki, Kohei Hayashi, et al. · Therapeutic Advances in Medical Oncology · 2
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies
2024 · Tomonori Araki, Machiko Kawahira, et al. · Oncology · 2
PDF
Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results.
2023 · Takashi Imajima, Tsuyoshi Shirakawa, et al. · Journal of Clinical Oncology · 2
PDF
An Extragastrointestinal Tumor Diagnosed as a Vaginal Mass during Pregnancy
2022 · Reo Ando, Shuichi Taniguchi, et al. · Case Reports in Obstetrics and Gynecology · 2
PDF
Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 study
2025 · Kazuo Nishikawa, Taiga Otsuka, et al. · BMC Cancer · 1
PDF
Chemotherapy‐induced neutropenia predicts short‐term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid
2025 · Tomonori Araki, Tsuyoshi Shirakawa, et al. · International Journal of Cancer · 1
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
2025 · Tomonori Araki, Yuki Sonoda, et al. · Scientific Reports · 1
PDF
Real-world evidence of nanoliposomal irinotecan and fluorouracil with folinic acid in patients with unresectable or recurrent pancreatic cancer: Final results of a multicenter observational study.
2025 · Yudai Shinohara, Tsuyoshi Shirakawa, et al. · Journal of Clinical Oncology · 1
PDF
MO61-6 Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer
2023 · Reina Kawasaki, Tsuyoshi Shirakawa, et al. · Annals of Oncology · 1
P-113 A multicenter observational study of liposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Retrospective part
2022 · T. Imajima, T. Shirakawa, et al. · Annals of Oncology · 1
Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid
2026 · Yujiro Ueda, Hiroki Taguchi, et al. · Scientific Reports
PDF
Current Status of Comprehensive Genomic Profiling (CGP) in Miyazaki Prefecture and Review of the Literature
2025 · KAWANO, Noriaki, KIKUCHI, Ikuo, et al. · Institutional Repositories DataBase (IRDB)
PDF
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON‐2 Study
2025 · Atsuko Kakihara, Shigeyuki Takeshita, et al. · Asia-Pacific Journal of Clinical Oncology
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study
2025 · Tomomi Koike, Yasunori Kawaguchi, et al. · Therapeutic Advances in Medical Oncology
A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401).
2025 · Tsuyoshi Shirakawa, Tomonori Araki, et al. · Journal of Clinical Oncology
PDF
346P Final results of multicenter prospective observational study of nano-liposomal irinotecan, fluorouracil and folinic acid in second-line chemotherapy for advanced pancreatic cancer: The NAPOLEON-2
2024 · K. Toyodome, S. Arima, et al. · Annals of Oncology
PDF
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservational study (NAPOLEON-2)
2024 · Tomoko Kodama, Takashi Imajima, et al. · Research Square
PDF
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observational study (NAPOLEON-2)
2023 · Tomoko Kodama, Takashi Imajima, et al. · Research Square
PDF
MO7-4 Impact of biliary drainage for pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil and folinic acid
2023 · Kazuo Nishikawa, Yoshihito Kubotsu, et al. · Annals of Oncology
Works count: 23
Citation count: 43
H-index: 3
I10-index: 1
Year
Topic
Type